Microcap Focus on Pharmacyte Biotech Inc (OTCMKTS:PMCB)


Pharmacyte Biotech Inc (OTCMKTS:PMCB) recently had a call to update shareholders about the progress about operations. Overall, the stock is trending downward this week. PMCB has been around for years and was initially incorporated as eFoodSafety.com, Inc. in 1996 in Nevada. The recent move up comes after PMCB outlined 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

The live-cell encapsulation technology employed by Pharmacyte Biotech is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed. Now, the transcript of the call was not released yet, but after the call, PMCB was hit was with some strong selling pressure, which raises some eyebrows.

Pharmacyte Biotech Inc (OTCMKTS:PMCB) frames itself as a clinical stage biotechnology company that focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes.

The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer.

It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the Cell-in-a-Box technology to develop therapies for cancer-based upon the constituents of the Cannabis plant.

The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Silver Spring, Maryland.

According to company materials, “PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.”

Find out when $PMCB stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Another interesting aspect of PMCB is their cannabinoid chapter and its research into treating cancer. This type of quote has brought a lot cannabis sector attention to the brand, which the company has not shied away from. Here  is the company’s CEO:

“The current U.S. medical Cannabis industry has been estimated to be worth about $3.0 billion, and it is expected to more than double as more states legalize the use of Cannabis as medicine. There are dozens of companies in the space. Multi-billion-dollar big pharma companies such as Merck, Sanofi-Aventis, AbbVie and Bristol-Meyers Squibb hold cannabinoid-related patents and are conducting cannabinoid-related research.”

Sporting a current market cap value of $38.93M, PMCB does not have much in the way of liabilities but the current pipleine needs to be under strict watch as the company’s candidates progress and test results come out. You can bet we will update this one again as new information comes into view. For continuing coverage on shares of $PMCB stock, as well as our other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!

Disclosure: we hold no position in $PMCB, either long or short, and we have not been compensated for this article.